NANJING, China, Nov. 10 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today its participation in the Morgan Stanley 7th Annual Asia Pacific Summit 2008. The conference will be held at the Mandarin Oriental Singapore on November 11-13, 2008.
Simcere's chief financial officer, Frank Zhigang Zhao, and vice president of marketing, Mark Chen, will attend the conference on Wednesday November 12. Frank Zhigang Zhao will give a company presentation to investors at 11:30am, which will take place on Amber Track, Level 1 of Mandarin Oriental Singapore. A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's website, located at http://www.simcere.com.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
CONTACT: For investor and media inquiries, please contact: ir@simcere.com;
Or In Nanjing: Frank Zhigang Zhao, Chief Financial Officer of Simcere
Pharmaceutical Group, +86-25-8556-6666 x8818; Or In Beijing: Kejia Wu of
Brunswick Group, +86-10-6566-4651; Or In Hong Kong: Joseph Lo Chi-Lun of
Brunswick Group, +852-3512-5033; Or In New York: Michael Guerin of
Brunswick Group LLC, +1-212-333-3810
Web site: http://www.simcere.com/
